Literature DB >> 6465176

Myocardial perfusion abnormalities in asymptomatic patients with systemic lupus erythematosus.

J D Hosenpud, A Montanaro, M V Hart, J E Haines, H D Specht, R M Bennett, F E Kloster.   

Abstract

Accelerated coronary artery disease and myocardial infarction in young patients with systemic lupus erythematosus is well documented; however, the prevalence of coronary involvement is unknown. Accordingly, 26 patients with systemic lupus were selected irrespective of previous cardiac history to undergo exercise thallium-201 cardiac scintigraphy. Segmental perfusion abnormalities were present in 10 of the 26 studies (38.5 percent). Five patients had reversible defects suggesting ischemia, four patients had persistent defects consistent with scar, and one patient had both reversible and persistent defects in two areas. There was no correlation between positive thallium results and duration of disease, amount of corticosteroid treatment, major organ system involvement or age. Only a history of pericarditis appeared to be associated with positive thallium-201 results (p less than 0.05). It is concluded that segmental myocardial perfusion abnormalities are common in patients with systemic lupus erythematosus. Whether this reflects large-vessel coronary disease or small-vessel abnormalities remains to be determined.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6465176     DOI: 10.1016/0002-9343(84)90704-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  11 in total

1.  [Cardiovascular monitoring of patients with systemic lupus erythematosus].

Authors:  H Schotte; H Becker; W Domschke; M Gaubitz
Journal:  Z Rheumatol       Date:  2005-11       Impact factor: 1.372

Review 2.  [Accelerated atherosclerosis in rheumatic systemic diseases as an example of systemic lupus erythematosus--what is the consequence?].

Authors:  R Fischer-Betz; S Beer; M Schneider
Journal:  Z Rheumatol       Date:  2005-05       Impact factor: 1.372

Review 3.  Atherosclerosis and systemic lupus erythematosus.

Authors:  M Urowitz; D Gladman; I Bruce
Journal:  Curr Rheumatol Rep       Date:  2000-02       Impact factor: 4.592

4.  The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction.

Authors:  Seth G Thacker; Celine C Berthier; Deborah Mattinzoli; Maria Pia Rastaldi; Matthias Kretzler; Mariana J Kaplan
Journal:  J Immunol       Date:  2010-08-30       Impact factor: 5.422

Review 5.  Epidemiology of atherosclerosis in systemic lupus erythematosus.

Authors:  Mandana Nikpour; Murray B Urowitz; Dafna D Gladman
Journal:  Curr Rheumatol Rep       Date:  2009-08       Impact factor: 4.592

Review 6.  Myocardial scintigraphy--25 years after start.

Authors:  G Hör
Journal:  Eur J Nucl Med       Date:  1988

7.  Atherosclerotic vascular disease in systemic lupus erythematosus.

Authors:  Matthew H Liang; Lisa A Mandl; Karen Costenbader; Ervin Fox; Elizabeth Karlson
Journal:  J Natl Med Assoc       Date:  2002-09       Impact factor: 1.798

8.  Myocardial perfusion scintigraphy and coronary disease risk factors in systemic lupus erythematosus.

Authors:  E M C Sella; E I Sato; W A Leite; J A Oliveira Filho; A Barbieri
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

9.  Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients.

Authors:  Emily C Somers; Wenpu Zhao; Emily E Lewis; Lu Wang; Jeffrey J Wing; Baskaran Sundaram; Ella A Kazerooni; W Joseph McCune; Mariana J Kaplan
Journal:  PLoS One       Date:  2012-05-14       Impact factor: 3.240

10.  Cardiovascular disease in systemic lupus erythematosus: the role of traditional and lupus related risk factors.

Authors:  Carlos Borelli Zeller; Simone Appenzeller
Journal:  Curr Cardiol Rev       Date:  2008-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.